Source comparison
Ipamorelin vs Tesamorelin + Ipamorelin Blend: Dosing, Receptor Dynamics, and Research Outcome Comparison
Primary Mechanism Selective GHSR-1a agonism (ghrelin pathway only) Dual-pathway: GHSR-1a + GHRH receptor activation Blend engages complementary pathways for broader metabolic coverage GH Peak Amplitude 8–10 ng/mL at 30 min (100 mcg dose) 9–11 ng/mL initial pea
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Selective GHSR-1a agonism (ghrelin pathway only)
- Dual-pathway: GHSR-1a + GHRH receptor activation
- Blend engages complementary pathways for broader metabolic coverage
- GH Peak Amplitude
- 8–10 ng/mL at 30 min (100 mcg dose)
- 9–11 ng/mL initial peak, sustained 4–6 ng/mL plateau 6–8 hours
- Blend produces 40–50% greater total GH AUC over 24 hours
- Typical Research Dosing
- 200–300 mcg/day split AM/PM (100–150 mcg per dose)
- 2 mg tesamorelin + 200 mcg ipamorelin daily (single evening dose or split protocol)
- Blend requires lower ipamorelin dose due to GHRH synergy
- Receptor Desensitisation Risk
- Minimal—no attenuation observed at 12 weeks stable dosing
- GHRH receptors show slight adaptation >16 weeks; rotation protocols recommended
- Ipamorelin's ghrelin selectivity prevents tachyphylaxis; GHRH component requires monitoring
- Visceral Fat Reduction
- Modest—GH lipolytic effects present but VAT-specific targeting limited
- Significant—15–18% VAT reduction observed in 26-week models (tesamorelin component drives this)
- Blend is the clear choice for abdominal adiposity research
- IGF-1 Elevation
- Moderate—transient IGF-1 peaks follow GH pulses but baseline IGF-1 increases are gradual
- Robust—sustained GHRH stimulation produces consistent 30–40% baseline IGF-1 elevation within 8 weeks
- Blend produces faster, more sustained IGF-1 restoration
- Best Research Application
- Pulsatile GH dynamics, sleep-GH interaction studies, anabolic signalling without metabolic confounders
- Metabolic dysfunction models, visceral adiposity research, GH/IGF-1 axis restoration, body recomposition protocols
- Match compound to research objective—no universal 'better' exists